Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Neurocrine Biosciences, Inc. shares valued at $421,828 were sold by Boyer David W. on Sep 13 ’24. At $121.88 per share, Boyer David W. sold 3,461 shares. The insider’s holdings dropped to 1,672 shares worth approximately $0.19 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, DAVID WARREN BOYER purchased 4,756 shares, netting a total of over 576,808 in proceeds.
Before that, RASTETTER WILLIAM H had sold 14,250 shares from its account. In a trade valued at $2,090,332, the Director traded Neurocrine Biosciences, Inc. shares for $146.69 each. Upon closing the transaction, the insider’s holdings decreased to 14,250 shares, worth approximately $4.19 million.
As published in a research note from Piper Sandler on August 29, 2024, Neurocrine Biosciences, Inc. [NBIX] has been rated up from a Neutral to an Overweight and the price target has been revised to $159 from $131. Analysts at Wells Fargo upgraded the stock from ‘”an Equal weight”‘ to ‘”an Overweight”‘ outlook in a report released in late April. Earlier on December 12, 2023, Deutsche Bank initiated its rating. Their recommendation was “a Buy” for NBIX stock.
Analyzing NBIX Stock Performance
During the last five days, there has been a drop of approximately -3.49%. Over the course of the year, Neurocrine Biosciences, Inc. shares have dropped approximately -15.09%. Shares of the company reached a 52-week high of $157.98 on 08/01/24 and a 52-week low of $110.95 on 10/03/24. A 50-day SMA is recorded $133.33, while a 200-day SMA reached $136.12. Nevertheless, trading volume fell to 1.32 million shares from 0.72 million shares the previous day.
Support And Resistance Levels for Neurocrine Biosciences, Inc. (NBIX)
According to the 24-hour chart, there is a support level at 110.54, which, if violated, would cause prices to drop to 109.19. In the upper region, resistance lies at 113.64. The next price resistance is at 115.39. RSI (Relative Strength Index) is 24.99 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -3.69, which suggests the price will decrease in the coming days. Percent R is at 92.63%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
